![]() |
|
|
Vol. 289, Issue 1, 329-333, April 1999
Departments of
Clinical Chemistry (J.v.A., O.v.T.) and
Experimental
Therapy (A.H.S.), the Netherlands Cancer Institute, Amsterdam, the
Netherlands; and
Department of Pharmacy, Slotervaart Hospital,
Amsterdam, the Netherlands (J.H.B.)
To determine the tissue-specific impact of P-glycoprotein on the
accumulation of a substrate drug, we have studied the tissue distribution of vinblastine in mdr1a(
/
) and
wild-type mice at approximately similar, relatively low plasma levels.
Vinblastine was administered as a 96-h continuous infusion at dose
rates of 1 to 10 µg/h, which were delivered by a s.c.-implanted
osmotic pump. Drug concentrations were determined in plasma and tissues by HPLC. In comparison to wild-type mice, 4.4- to 9.6-fold higher drug
concentrations were observed in the brains of
mdr1a(
/
) mice (p
.014),
whereas a 2-fold increase was found in the heart (p = .014) and the intestinal tissues (p
.028). No
or only slight differences were observed in all other tissues. These
results indicate that, except for the brain and, to a lesser extent,
the heart and the intestinal tissues, P-glycoprotein does not protect individual organs against vinblastine. Given its polarized
cell-specific and organ-specific distribution and its affinity for a
broad range of compounds, it is suggested that P-glycoprotein has
mainly evolved to provide a general protection of the complete organism
against potentially toxic substrates by inhibiting their uptake and by mediating their transport from the internal to the external
environment. For the clinical application of reversal agents, these
data indicate that, in general, a blockade of endogenous P-glycoprotein
will probably not result in an increased accumulation of the
coadministered anticancer drug in complete organs, but, possibly, only
in classes of cells making up a fraction of an organ.
This article has been cited by other articles:
![]() |
L. Couture, J. A. Nash, and J. Turgeon The ATP-Binding Cassette Transporters and Their Implication in Drug Disposition: A Special Look at the Heart. Pharmacol. Rev., June 1, 2006; 58(2): 244 - 258. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Davis Gender Differences in p-Glycoprotein: Drug Toxicity and Response J. Clin. Oncol., September 10, 2005; 23(26): 6439 - 6440. [Full Text] [PDF] |
||||
![]() |
D. S. Cox, K. R. Scott, H. Gao, and N. D. Eddington Effect of P-Glycoprotein on the Pharmacokinetics and Tissue Distribution of Enaminone Anticonvulsants: Analysis by Population and Physiological Approaches J. Pharmacol. Exp. Ther., September 1, 2002; 302(3): 1096 - 1104. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Weiss and W. Kang P-Glycoprotein Inhibitors Enhance Saturable Uptake of Idarubicin in Rat Heart: Pharmacokinetic/Pharmacodynamic Modeling J. Pharmacol. Exp. Ther., February 1, 2002; 300(2): 688 - 694. [Abstract] [Full Text] [PDF] |
||||